• Find people
• Intranet

Gastroesophageal Carcinogenesis Manuel Pera

Publications 2025 (13)

• Alsina-Maqueda M^*, Teijo-Quintáns A, Cuatrecasas M, Fernández-Aceñero MJ, Fernández-Montes A, Gómez-Martínez C, Jiménez Fonseca P, Martínez-Ciarpaglini C, Rivera-Herrero F, Iglesias M^*. Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol . 2025: (en Premsa).
• He J, Alhamwe BA, Sabroso S, Carrato A, Hidalgo M, Molero X, Iglesias M, Perea J, Farré A, Tardón A, Domínguez-Muñoz E, Barberá V, Muñoz-Bellvis L, Löhr M, Greenhalf W, O'Rorke M, Gress T, Crnogorac-Jurcevic T, Gayà A, Langtry A, Kleeff J, Lawlor R, Real FX, Renz H, Malats N^*, Rodríguez-Garrote M, PanGenEU Study Investigators (...,López de Maturana E, Gomez-Rubio P, Molina-Montes E, Alonso L, Márquez M, Milne R, Alfaro A, Lobato T, Estudillo L, Scarpa A, Beghelli E, Sharp L, O'Driscoll D, Álvarez-Gallego R, Cubillo A, Peinado P, Salas I, Rodríguez-Pascual J, Caminoa A, Guillén-Ponce C, Longo-Muñoz F, Ferreiro R, Pachón V, Vaz MA, Iglesias M, Ilzarbe L, Álvarez C, Bessa X, Bory F, Márquez L, Poves-Prim I, Burdío F, Grande L, Gimeno J, Guarner L, Balcells J, Salcedo M, Merino X, Michalski C, Esposito I, Kong B, Huang L, Verbeke C, Ye W, Yu J, Loinaz C, Rodríguez Peralto J.L, Teijo-Quintáns A, Peláez P, Mora J, Martín M, Guarner C, Artigas V, Sancho FJ, Concepción M, Ramón y Cajal T, Szafranska J, Costello E, Murray L, Cantwell M, Barberá V, Gallego J, Barneo L, Lozano A, Lauces M, Sayagués-Manzano JM, Gutíerrrez-Troncoso ML, Orfao de Matos A, Buchholz M, Neesse A, Kocher HM, Bhattacharya S, Abraham AT, Ennis D, Dowe T, Radon T, Silverman DT, Easton D,...). Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Int J Cancer 2025; 157(3): 468-479.
• Vinaixa J, Martínez-Bosch N, Gibert J, Manero-Rupérez N, Santofimia-Castaño P, Baudou FG, Vera RE, Pease DR, Iglesias M, Sen S, Wang X, Almada LL, Marks DL, Moreno M, Iovanna JL, Rabinovich GA^*, Fernández-Zapico ME^*, Navarro P^*. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc. Natl. Acad. Sci. U. S. A. 2025; 122(14): e2424051122.
• Canillas L, Pelegrina A, León FW, Salis A, Colominas-González E, Caro A, Sanchez J, Alvarez J, Burdío F, Carrion JA^*. Clinical Ascites and Emergency Procedure as Determinants of Surgical Risk in Patients with Advanced Chronic Liver Disease. J Clin Med 2025; 14(4): 1077.
• Martelli V, Vidal J, Salvans S, Fernández Rodríguez C, Badia J, Linares JL, Jimenez M, Sibilio A, Gibert J, Pérez M, Bellosillo B, Calon A, Pietrantonio F, Iglesias M, Pascual M, Montagut C^*. Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives. Cancers 2025; 17(9): 1461.
• Pelc Z, Sedlak K, Endo Y, Van Sandick J, Gisbertz S, Pera MR, Baiocchi GL, Morgagni P, Framarini M, Hoelscher A, Moenig S, Kolodziejczyk P, Gockel I, Piessen G, Eveno C, Matos da Costa P, Davies A, Baker C, Allum W, Fumagalli Romario U, Rosati R, Reim D, D'ugo D, Wijnhoven B, De Manzoni G, Kielan W, Schneider P, Badgwell BB, Pawlik TM, Polkowski W, Rawicz-Pruszynski K^*. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis - Joint analysis of European GASTRODATA and American national cancer database. Am J Surg 2025; 242: 116235.
• Guerrero MA, Pellino G, Pascual M, Gimeno M, Alonso S, Podda M, Toledano M, Núñez-Alfonsel J, Selvaggi L, Acosta-Mérida MA, Bellido J, Ielpo B^*, ROBOCOSTES Collaborative Group. Cost-effectiveness of robotic compared with laparoscopic rectal resection. Results from the Spanish prospective national trial ROBOCOSTES. Surgery 2025; 180: 109134.
• Markar S, Mariette C, Bonnetain F, Lundell L, Rosati R, De Manzoni G, Bonavina L, Tucker O, Plum P, D'Journo XB, Van Daele D, Cogill G, Santi S, Farran L, Iranzo V, Pera MR, Veziant J, Piessen G^*. Immunonutrition to improve the quality of life of upper gastrointestinal cancer patients undergoing neoadjuvant treatment prior to surgery (NEOIMMUNE): double-blind randomized controlled multicenter clinical trial. Dis Esophagus 2025; 38(1): doae113.
• Veas-Rodriguez J, Piñol M, Sorolla MA, Parisi E, Sorolla A, Santacana M, Ruiz M, Parra G, Bernabeu M, Iglesias M, Aracil C, Escartin A, Vilardell F, Matías-Guiu X, Salud A, Montal R^*. Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. J IMMUNOTHER CANCER 2025; 13(3): e010024.
• Lop-Gros J^*, Santiago-Díaz P, Larrubia-Loring M, Patriarca ME, Lloveras B, Iglesias M. Claudin 18.2 Immunohistochemistry Expression in Gastric Cancer: A Systematic Review. Appl. Immunohistochem. 2025; 33(2): 61-69.
• Canillas L, Pelegrina A, Álvarez-García JC, Carrion JA^*. Portal hypertension or histologic characteristics of the liver?. J Gastrointest Surg 2025; 29(2): 101881.
• Amat-Fernandez C, Pardo Y^*, Ferrer M, Bosch-Duran G, Lizano C, Briseño-Renata R, Vernet-Tomas M, Fumadó L, Beisani M, Redondo D, Bach-Pascual A, Garin O^*, Hospital de Mar Patient-Reported Measures Group (...,Pont A, Zamora V, Argudo N, Bach-Pascual A, Benaiges D, Castells X, Cecchini L, Chamoun B, Hurtado-Ortuño M, Noguera A, Perez-Piñero M, Pérez Sáez MJ, Servitja S, Villatoro M, Valderas JM,...). Evaluating the implementation of PROMs and PREMs in routine clinical care: co-design of tools from the perspective of patients and healthcare professionals. Health Qual Life Outcomes 2025; 23(1): 15.
• Khoury-Damaa M, Serizay J, Balagué R, Boudjema AR, Faucourt M, Delgehyr N, Goh KJ, Lu H, Tan EK, James CT, Faucon C, Mitri R, Bracht DC, Bingle CD, Dunn NR, Arnold SJ, Zaragosi LE, Barbry P, Koszul R, Omran H, Gil-Gómez G, Escudier E, Legendre M, Roy S, Spassky N, Meunier A^*. Cyclin O controls entry into the cell-cycle variant required for multiciliated cell differentiation. Cell Rep 2025; 44(1): 115117.